Thomas Thevenet

3.5k total citations · 1 hit paper
7 papers, 289 citations indexed

About

Thomas Thevenet is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Thomas Thevenet has authored 7 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Epidemiology and 4 papers in Neurology. Recurrent topics in Thomas Thevenet's work include Neuroblastoma Research and Treatments (4 papers), Neuroendocrine Tumor Research Advances (4 papers) and Lung Cancer Research Studies (4 papers). Thomas Thevenet is often cited by papers focused on Neuroblastoma Research and Treatments (4 papers), Neuroendocrine Tumor Research Advances (4 papers) and Lung Cancer Research Studies (4 papers). Thomas Thevenet collaborates with scholars based in United States, Germany and Spain. Thomas Thevenet's co-authors include Matthew H. Kulke, Timothy J. Hobday, Kjell Öberg, Beth Chasen, David Bushnell, Eric P. Krenning, Pamela L. Kunz, Andrew Hendifar, Philippe Ruszniewski and Edward M. Wolin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Dermatological Science.

In The Last Decade

Thomas Thevenet

5 papers receiving 288 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial

2018 272 citations Jonathan Strosberg, Edward M. Wolin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Thomas Thevenet

Since Specialization

Citations

This map shows the geographic impact of Thomas Thevenet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Thevenet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Thevenet more than expected).

Fields of papers citing papers by Thomas Thevenet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Thevenet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Thevenet. The network helps show where Thomas Thevenet may publish in the future.

Co-authorship network of co-authors of Thomas Thevenet

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Thevenet. A scholar is included among the top collaborators of Thomas Thevenet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Thevenet. Thomas Thevenet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	685TiP A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age 2024 ·Annals of Oncology ·(unknown), Kenneth J. Cohen, Stepan Melnyk, (unknown), Thomas Thevenet	1
2	Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial. 2023 ·Journal of Clinical Oncology ·Þorvarður R. Hálfdánarson, Jaume Capdevila, Daniel M. Halperin, Ken Herrmann, Grace Kong, (unknown), Josh Mailman, Diane Reidy‐Lagunes, Rajaventhan Srirajaskanthan, (unknown), (unknown), Thomas Thevenet	0
3	COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care 2023 ·Endocrine Abstracts ·(unknown), (unknown), Diane Reidy‐Lagunes, Grace Kong, Jaume Capdevila, Josh Mailman, Ken Herrmann, (unknown), (unknown), Thomas Thevenet, Philip Harris	1
4	Pivotal phase III COMPOSE trial to compare lutetium (177Lu) edotreotide with best standard of care in patients with well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors 2023 ·Endocrine Abstracts ·Jaume Capdevila, Daniel M. Halperin, Diane Reidy‐Lagunes, Grace Kong, (unknown), Josh Mailman, Ken Herrmann, (unknown), Thomas Thevenet, Philip Harris	0
5	Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial breakdown → 2018 ·Journal of Clinical Oncology ·Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, (unknown), Philippe Ruszniewski, Eric P. Krenning, (unknown)	272
6	Measles virus infection of human keratinocytes: Possible link between measles and atopic dermatitis 2017 ·Journal of Dermatological Science ·(unknown), Cyrille Mathieu, Thomas Thevenet, (unknown), Jean‐François Jégou, Cindy G. Boer, Katarzyna Tomczak, Louis-Marie Bloyet, (unknown), Sophie Grande, C. Goujon, Catherine Cornu, Branka Horvat	12
7	Oncostatic effects of Alangium vitiense extracts (ICIG-EORTC 1131, 1186 and 1207) on lymphoid murine tumors. 1978 ·PubMed ·G Mathé, M. Hayat, E. Chenu, H.‐P. HUSSON, Thomas Thevenet, Kan Chen, Patrick Potier	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact